![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
September 17, 2024
A conversation with study chair James M. Ford, MD
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
December 19, 2023
The co-chairs reflect on the year's key accomplishments and look ahead to 2024
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
October 19, 2023
Matthias Weiss, MD, of ThedaCare, and Kim Reiss, MD, of the University of Pennsylvania, discuss current trends in precision oncology
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence